ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

J&J's Simponi Helps Colitis Patients In Clinical Trial

By Peter Loftus Of DOW JONES NEWSWIRES Johnson & Johnson (JNJ) said its drug Simponi improved symptoms in a majority of patients with an inflammatory-bowel disease in a new clinical trial. The results, released at a medical conference Monday, could support expansion of the approved uses of Simponi to include treating the bowel condition, known as ulcerative colitis, which J&J estimates affects about 700,000 people in the U.S. Simponi, which was introduced in 2009, is currently approved to treat signs and symptoms of moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. Simponi is known as an anti-tumor necrosis factor, or anti-TNF, a category that also includes J&J's older drug, Remicade, which is already approved to treat ulcerative colitis. Simponi can be self-administered by patients as an injection, while Remicade requires intravenous infusion by a health-care provider. J&J recorded $410 million in Simponi sales for 2011; Merck & Co. (MRK), which markets the drug in certain countries outside the U.S., recorded $264 million in Simponi sales for 2011. J&J tested Simponi in a late-stage clinical trial of more than 770 patients with moderately to severely active ulcerative colitis who had failed to respond to or tolerate certain other treatments. Some patients received Simponi--at two different dose levels--and some received a placebo, and researchers tracked how many experienced a clinical response at six weeks after the start of treatment. Clinical response included improvements in various symptoms of ulcerative colitis such as diarrhea. According to J&J, 51.8% and 55% of patients in the two Simponi groups, respectively, achieved a clinical response at week 6, versus 29.7% of placebo patients. The results were presented Monday at the Digestive Disease Week medical meeting in San Diego. In a secondary measure in the trial, roughly 18.7% and 17.8% of patients in the Simponi groups had clinical remission, versus 6.3% in placebo patients. The rates of adverse events were comparable among the Simponi and placebo groups, and J&J said the safety of Simponi in the colitis study was consistent with the drug's safety profile in the diseases for which it's already approved. As a class of drugs, Simponi and other anti-TNFs are associated with increased risk of infections and certain forms of cancer such as lymphoma. The data suggest Simponi could be a new treatment option for ulcerative colitis patients who don't respond to other drugs, or who prefer the convenience of a subcutaneous injection, said William Sandborn, chief of the division of gastroenterology at the University of California, San Diego, and lead investigator of the J&J-funded study. J&J also has studied Simponi over a longer treatment duration in colitis patients, and results are expected later this year. J&J plans to apply for U.S. and European regulatory approval of Simponi as a treatment for ulcerative colitis this year, said J&J spokesman Brian Kenney. Abbott Laboratories (ABT) also has applied for regulatory approval of its anti-inflammatory drug, Humira, as a treatment for ulcerative colitis. European regulators have approved the new indication. Last year, the FDA declined to approve J&J's requests to market Simponi's ability to inhibit progression of structural damage in both rheumatoid arthritis and psoriatic arthritis. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
08/04/201514:43:05Statement of Changes in Beneficial Ownership (4)
08/04/201514:43:05Statement of Changes in Beneficial Ownership (4)
07/31/201519:27:51WHO Says Ebola Vaccine Effective in African Trial -- Update
07/31/201515:16:17WHO Says Ebola Vaccine Effective in African Trial -- Update
07/31/201509:00:04WHO Says Ebola Vaccine Effective in African Trial
07/31/201509:00:03WHO Says Ebola Vaccine Effective in African Trial -- Update
07/31/201508:47:49WHO Says Ebola Vaccine Effective in African Trial
07/31/201508:10:00In Interim Results from Phase 3 Study, Merck’s Investigational E...
07/30/201508:00:00Celebrity Chef Leticia Moreinos Schwartz, Merck and the American...
07/28/201517:00:35Gilead Sales Soar on Hepatitis Drugs
07/28/201516:34:36Current Report Filing (8-k)
07/28/201516:15:00Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board...
07/28/201512:26:16Merck Earnings Hurt by Arthritis Drug Knockoffs
07/28/201508:23:48Merck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker--Update
07/28/201508:20:10Merck Earnings Top Views Amid Cost Cuts
07/28/201508:12:33Merck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker
07/28/201507:07:41Current Report Filing (8-k)
07/28/201507:00:00Merck Announces Second-Quarter 2015 Financial Results
07/28/201506:45:00Merck Enhances Immuno-Oncology Portfolio with Acquisition of...
07/28/201506:30:00Merck Announces U.S. Food & Drug Administration Acceptance of...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad